You are here: Industry Insights > Exelixis

News List

Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX (cabozantinib) in Combination with OPDIVO (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carci firstwordpharma
August 26, 2021
Exelixis, Inc. (Nasdaq: EXEL) today announced Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX® (cabozantinib) in Japan, and Ono Pharmaceutical Co., Ltd. (Ono).
Novasep, Exelixis Ink ADC Manufacturing Agreement contractpharma
July 07, 2021
Covers the cGMP clinical manufacturing of a next-generation ADC drug candidate.
Exelixis Acquires GamaMabs Oncology Antibody Program contractpharma
May 06, 2021
Exelixis, Inc. and GamaMabs Pharma have entered an agreement under which Exelixis will acquire all rights to GamaMabs’ AMHR2 antibody technology.
Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors americanpharmaceuticalreview
April 07, 2021
Exelixis, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of XB002 in patients with ...
Exelixis, NBE join forces for discovery and development of ADCs for cancer pharmaceutical-business-review
September 24, 2020
Exelixis and NBE-Therapeutics announced a partnership to discover and develop multiple antibody-drug conjugates (ADCs) for oncology applications by leveraging NBE’s unique expertise and proprietary platforms in ADC discovery, including site-specific ...
Exelixis and Catalent Enter ADC Partnership contractpharma
September 17, 2020
Collaboration, license and exclusive option agreement to develop antibody-drug conjugates leveraging SMARTag bioconjugation technology.
Exelixis initiates phase 3 trial of Cabozantinib/Atezolizumab combo in prostate cancer pharmaceutical-business-review
July 06, 2020
Exelixis, Inc. announced the initiation of CONTACT-02, a global phase 3 pivotal trial of cabozantinib (CABOMETYX) in combination with atezolizumab (TECENTRIQ) in patients with metastatic castration-resistant prostate cancer (CRPC) who have been ...
Exelixis, Aurigene to develop novel therapies for cancer biospectrumasia
August 05, 2019
Companies will partner to advance small molecules in up to six discrete projects, including three existing programs against specific predetermined targets
Exelixis signs drug licensing deal with Aurigene pharmaceutical-technology
August 02, 2019
US-based biotechnology company Exelixis has signed an exclusive collaboration, option and license agreement with India-based Aurigene Discovery Technologies for discovery and development of new oncology treatments.
Exelixis enters crowded liver cancer field with Cabometyx, taking on Bayer, BMS and Merck fiercepharma
January 17, 2019
Exelixis’ fast-growing tyrosine kinase inhibitor Cabometyx just added another FDA approval. It can now treat liver cancer patients if Bayer’s Nexavar is no longer helpful, putting it in a field that’s already crowded with Bayer’s Stivarga and some checkpo

Previous page 1 2 Next page